Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 221Carcinoma, Non-Small-Cell Lung 218Prostatic Neoplasms 150Multiple Myeloma 140Neoplasms 129Colorectal Neoplasms 117Leukemia, Myeloid, Acute 106Lung Neoplasms 102Neoplasm Metastasis 95Squamous Cell Carcinoma of Head and Neck 91Carcinoma, Hepatocellular 84Lymphoma 78Melanoma 77Triple Negative Breast Neoplasms 71Pancreatic Neoplasms 71Ovarian Neoplasms 66Sarcoma 64Lymphoma, Large B-Cell, Diffuse 61Carcinoma, Renal Cell 59Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Head and Neck Neoplasms 57Recurrence 56Brain Neoplasms 56Lymphoma, Non-Hodgkin 53Hematologic Neoplasms 52Stomach Neoplasms 51Leukemia, Lymphocytic, Chronic, B-Cell 51Endometrial Neoplasms 50Small Cell Lung Carcinoma 48Rectal Neoplasms 46

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Mucinous Adenocarcinoma × 90 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡